Journal of Pharmaceutical Research
DOI: 10.18579/jopcr/v20.1.sushanth
Year: 2021, Volume: 20, Issue: 1, Pages: 1-7
Original Article
B Borsania Sushant1, S Kavitha1,∗
1Department of Pharmaceutical Chemistry, Krupanidhi College of Pharmacy, Bangalore, Karnataka, India
Ischaemia reperfusion-induced myocardial injury is a major issue, especially in diabetes, where oxidative stress enhances myocardial dysfunction. The therapeutic applications of garlic homogenate, repaglinide, and amlodipine have not been well studied. This study aims to examine the impact of Garlic homogenate, Repaglinide, and Amlodipine on Myocardial Injury in Diabetic Rats post Ischemia-Reperfusion. Diabetes was induced in Sprague-Dawley rats using a single intraperitoneal administration of alloxan. A 10-day treatment with garlic homogenate, repaglinide, and amlodipine followed by I/R-induced myocardial injury was performed. Cardiac function recovery was evaluated by contractile force, and biochemical studies were carried out using lactate dehydrogenase and creatine kinase-MB (CK-MB). Antioxidant status was studied by estimating superoxide dismutase, catalase activity, and TBARS levels. Histopathological analysis of myocardial and pancreatic tissues was performed. Triple co-treatment of diabetic rats with garlic extract, repaglinide, and amlodipine resulted in maximum antioxidant activity, lowered myocardial enzyme activity (LDH and CK-MB), and improved recovery of heart function after I/R injury. The combination of garlic extract, repaglinide, and amlodipine treatment resulted in the highest levels of SOD and catalase and the lowest amount of TBARS compared to dual or single therapies. Histopathological findings demonstrated that the triple therapy maintained myocardial integrity better than the other therapies did. This study offers new evidence that the combination of amlodipine, repaglinide, and garlic homogenate provides better cardioprotective effects against ischaemia-reperfusion injury in diabetic rats.
Keywords: Diabetes, Garlic, Repaglinide, Amlodipine, Myocardial Injury
© 2025 Published by Krupanidhi College of Pharmacy. This is an open-access article under the CC BY-NC-ND license (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Subscribe now for latest articles and news.